The South & Central America radiopharmaceutical theranostics market was valued at US$ 129.48 million in 2022 and is expected to reach US$ 233.71 million by 2028; it is estimated to register a CAGR of 10.3% from 2022 to 2028.
Based on radioisotype, the South & Central America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the South & Central America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the South & Central America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America radiopharmaceutical theranostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the South & Central America radiopharmaceutical theranostics market.
Reasons to Buy
Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies fuel the South & Central America Radiopharmaceutical Theranostics Market
Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for Lu-177-PSMA and Lu-177-DOTATATE) into all patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed qualities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are difficult to control. A fixed administered dosage results in the under treatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players.South & Central America Radiopharmaceutical Theranostics Market Overview
The South & Central America radiopharmaceutical theranostics market is segmented into the Argentina, Brazil, and the rest of South & Central America. The market growth in this region is due to the increasing prevalence of cancer and cardiovascular diseases, and presence of supportive government plans. Growing diabetes who are prone to cardiovascular disease is promoting the growth of radiopharmaceutical theranostics market in Brazil. Further, expanding healthcare expenditure in Brazil is boosting the radiopharmaceutical theranostics market.South & Central America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
South & Central America Radiopharmaceutical Theranostics Market Segmentation
The South & Central America radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the South & Central America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.Based on radioisotype, the South & Central America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the South & Central America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the South & Central America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America radiopharmaceutical theranostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the South & Central America radiopharmaceutical theranostics market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central Americaradiopharmaceutical theranostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central Americaradiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central Americaradiopharmaceutical theranostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. South & Central America Radiopharmaceutical Theranostics Market - Market Landscape
5. South & Central America Radiopharmaceutical Theranostics Market - Key Market Dynamics
6. Radiopharmaceutical Theranostics Market - South & Central America Analysis
7. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type
8. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope
9. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Source
10. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Application
11. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Indication
12. South & Central America Radiopharmaceutical Theranostics Market Analysis - by End User
13. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis
14. Radiopharmaceutical Theranostics Market - Industry Landscape
15. Company Profiles
16. Appendix
List of Tables
List of Figures
Companies Mentioned
- Bayer AG
- Curium
- Telix Pharmaceuticals Ltd.
- Siemens Healthineers
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value in 2022 | 129.48 Million |
| Forecasted Market Value by 2028 | 233.71 Million |
| Compound Annual Growth Rate | 10.3% |
| No. of Companies Mentioned | 4 |
